2 unchanged sentences
directors and officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during
−Removed: the Company's fiscal quarter ended July 31, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934,
+Added: the Company's fiscal quarter ended October 31, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of
+Added: 1934, as amended).
Exhibit Description
7 unchanged sentences
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the registration statement on Form S-1 filed with the SEC on May 10, 2021).
−Removed: Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on May 9, 2024).
−Removed: Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the SEC on May 9, 2024).
+Added: At-The-Market Issuance Sales Agreement, dated October 3, 2024, with Ascendiant Capital Markets, LLC (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on October 3, 2024).
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
19 unchanged sentences
ALZAMEND NEURO, INC.
−Removed: September 11, 2024
+Added: December 11, 2024
/s/ Stephan Jackman
1 unchanged sentence
Chief Executive Officer (principal executive officer)
−Removed: September 11, 2024
+Added: December 11, 2024
Chief Financial Officer (principal financial and accounting officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.